[Navelbine (vinorelbine): a review of its antitumor activity and toxicity in clinical studies].
Navelbine is a derivative of vinca alkaloid that interferes with tubulin assembly and exhibits antitumor activity. Clinical trials with single-agent Navelbine proved it to be effective against non-small cell lung cancer (NSCLC), breast cancer, and other tumors. At present, clinical trials by combination with various drugs are ongoing NSCLC and breast cancer. Navelbine+cisplatin is considered to be a standard therapy for NSCLC in Europe and SWOG. In breast cancer, the combination chemotherapy of Navelbine with anthracyclines, 5-FU, and other agents has been reported to be effective. The main adverse reactions caused by Navelbine are leukopenia and neutropenia. It causes less nerve neuropathy than vindesine. As Navelbine is a central therapeutic drug in combination therapy for NSCLC, more effective combination therapy with it are expected to be developed.
Niitani
H
H
Tokyo Cooperative Oncology Group.
D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy; D002986:Clinical Trials as Topic; D017321:Clinical Trials, Phase I as Topic; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy; D011838:Radiation-Sensitizing Agents / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use; D014747:Vinblastine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000737:chemistry / Q000627:therapeutic use; D000077235:Vinorelbine
D000972:Antineoplastic Agents, Phytogenic; D011838:Radiation-Sensitizing Agents; D014747:Vinblastine; D000077235:Vinorelbine